Impaired 11β-Hydroxysteroid Dehydrogenase Type 2 Activity in Kidney Disease Disrupts 11-Oxygenated Androgen Biosynthesis
Authors' conclusion
This is the first in vivo study to confirm a central role for renal HSD11B2 in 11-oxygenated androgen biosynthesis. Determining the clinical implications of this observation for patients with CKD requires further research.
Study context
- Population
- Patients with chronic kidney disease (CKD) and healthy controls; serum and urinary glucocorticoids, classic and 11-oxygenated androgens by liquid chromatography tandem mass spectrometry
- Participants
- 85 vs 46
- Exposure
- CKD vs healthy controls
- CKDn = 85
- Healthy controlsn = 46reference
- Outcome
- HSD11B2 activity (cortisol/cortisone ratio)
Methodological detailsobservational, complementary cell culture and computational modeling
- Observational
- Complementary cell culture and computational modeling
Main finding
As reported in the abstract
- HSD11B2 activity declined with estimated glomerular filtration rate (eGFR)
- CKD vs Healthy controls: P < 0.0001
Observational data: associations, not effects.
Further findings
| Outcome | P value |
|---|---|
| Serum cortisone, 11KA4, 11KT and 11β-hydroxytestosteroneLower in CKD | P < 0.0001 for each |
Computational model
- Model confirmed HSD11B2 as the key enzyme responsible for reduced 11-oxygenated androgen biosynthesis in CKD
- Predicted HSD11B2 expression correlated with eGFR
Original publication
Impaired 11β-Hydroxysteroid Dehydrogenase Type 2 Activity in Kidney Disease Disrupts 11-Oxygenated Androgen Biosynthesis. J Clin Endocrinol Metab. Published 9 October 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →